Glaxo wins $41M defense contract on biothreats
GlaxoSmithKline P.L.C. today said that it has received a five-year, $41 million contract from the Defense Threat Reduction Agency of the U.S. Department of Defense.
GlaxoSmithKline P.L.C. today said that it has received a five-year, $41 million contract from the Defense Threat Reduction Agency of the U.S. Department of Defense.
Glaxo agreed to develop a new class of antibacterials against Gram negative biothreats, such as Pseudomonas, Klebsiella and Acinetobacter, which are increasingly resistant to all known classes of antibiotics.
Gram negative bacteria are difficult to treat because their outer membrane interferes with drug penetration. New treatments must not only poison the pathogen, but still pass into the cell.
Glaxo shares were down 37 cents, to $52.50 in 10:30 a.m. trading on the New York Stock Exchange.
